Ad
related to: hepatic steatosis with surface nodularity due to pneumonia- Learn More Today
Explore NASH, uncover the risks,
and stay informed.
- NASH With Fibrosis
Learn about the basics of NASH
on the official HCP website.
- Sign Up For Updates
Stay informed on the latest
NASH news and information.
- About NASH
Learn more about the consequences
of NASH and patient management.
- Learn More Today
Search results
Results from the WOW.Com Content Network
Fatty liver disease (FLD), also known as hepatic steatosis and steatotic liver disease (SLD), is a condition where excess fat builds up in the liver. [1] Often there are no or few symptoms. [ 1 ] [ 2 ] Occasionally there may be tiredness or pain in the upper right side of the abdomen . [ 1 ]
Metabolic dysfunction–associated steatotic liver disease (MASLD), previously known as non-alcoholic fatty liver disease (NAFLD), [a] is a type of chronic liver disease. This condition is diagnosed when there is excessive fat build-up in the liver (hepatic steatosis), and at least one metabolic risk factor.
Liver cirrhosis on CT imaging of the abdomen in transverse view. Portable ultrasound is a low cost tool to identify the sign of liver surface nodularity with a good diagnostic accuracy. [72] Cirrhosis is also diagnosable through a variety of new elastography techniques. [73] [74] When a liver becomes cirrhotic it will generally become stiffer ...
Steatosis, also called fatty change, is abnormal retention of fat within a cell or organ. [1] Steatosis most often affects the liver – the primary organ of lipid metabolism – where the condition is commonly referred to as fatty liver disease. Steatosis can also occur in other organs, including the kidneys, heart, and muscle. [2]
Nodular regenerative hyperplasia (NRH) is a rare liver disease, characterised by the growth of nodules within the liver, resulting in liver hyperplasia.While in many cases it is asymptomatic and thus goes undetected – or is only discovered incidentally while investigating some other medical condition – in some people it results in non-cirrhotic portal hypertension (NCPH).
The hepatopulmonary syndrome results from the formation of microscopic intrapulmonary arteriovenous dilatations in patients with both chronic, and far less commonly acute liver failure. The mechanism is unknown but is thought to be due to increased liver production or decreased liver clearance of vasodilators, possibly involving nitric oxide. [1]
Ultrasound, CT, and MRI can all identify steatosis (fatty changes) of the liver tissue and nodularity of the liver surface suggestive of cirrhosis. [73] [74] CT and especially MRI are able to provide a higher level of detail, allowing visualization and characterize such structures as vessels and tumors within the liver. [75]
Steatohepatitis is a type of fatty liver disease, characterized by inflammation of the liver with concurrent fat accumulation in liver. Mere deposition of fat in the liver is termed steatosis, and together these constitute fatty liver changes. [1] There are 2 main types of fatty liver disease (FLD):
Ad
related to: hepatic steatosis with surface nodularity due to pneumonia